Clofazimine and moxifloxacin PK, safety and AccepTAbiLitY for paediatric TB treatment (CATALYST) - Trial PHRR210930-003966
Access comprehensive clinical trial information for PHRR210930-003966 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by STELLENBOSCH UNIVERSITTY and is currently Ongoing. The study focuses on Tuberculosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR210930-003966
Phase 1/2
Ongoing
Trial Details
Philippine Health Research Registry • PHRR210930-003966
Clofazimine and moxifloxacin PK, safety and AccepTAbiLitY for paediatric TB treatment (CATALYST)
The pharmacokinetics, safety and acceptability of new child-friendly formulations of clofazimine and moxifloxacin in children routinely treated for rifampicin-resistant tuberculosis
Study Focus
Interventional
Sponsor & Location
STELLENBOSCH UNIVERSITTY
UNITAID
India Philippines South Africa
Timeline & Enrollment
Phase 1/2
Oct 28, 2020
N/A
ICD-10 Classifications
Tuberculosis
Latent tuberculosis
Tuberculosis of other organs
Congenital tuberculosis
Sequelae of tuberculosis
Data Source
Philippine Health Research Registry
PHRR210930-003966
Non-Device Trial